ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,827.04
-1.54%
Dow Jones
41,938.45
-1.63%
US Dollar vs MXN
20.8206
0.52%
Brent Oil
80.17
-0.55%
Bitcoin
92,908.29
-1.68%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vigil Neuroscience Inc (VIGL)

  7. Vigil Neuroscience Inc (VIGL) Noticias

VIGL

Vigil Neuroscience (VIGL)

Vigil Neuroscience Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VIGL
FechaHoraFuenteTítuloSímboloCompañía
08/01/202515:05GlobeNewswire Inc.Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 MilestonesNASDAQ:VIGLVigil Neuroscience Inc
19/12/202417:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
14/11/202409:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VIGLVigil Neuroscience Inc
12/11/202406:00GlobeNewswire Inc.Vigil Neuroscience to Present at Upcoming Investor ConferencesNASDAQ:VIGLVigil Neuroscience Inc
07/11/202406:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
07/11/202406:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
07/11/202406:00GlobeNewswire Inc.Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
05/11/202406:00GlobeNewswire Inc.Vigil Neuroscience to Present at Guggenheim Healthcare Innovation ConferenceNASDAQ:VIGLVigil Neuroscience Inc
09/10/202417:22Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:VIGLVigil Neuroscience Inc
19/09/202416:20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VIGLVigil Neuroscience Inc
17/09/202406:00GlobeNewswire Inc.Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927NASDAQ:VIGLVigil Neuroscience Inc
16/09/202415:05GlobeNewswire Inc.Vigil Neuroscience to Present at Cantor Global Healthcare ConferenceNASDAQ:VIGLVigil Neuroscience Inc
29/08/202406:00GlobeNewswire Inc.Vigil Neuroscience to Present at Upcoming September Investor ConferencesNASDAQ:VIGLVigil Neuroscience Inc
13/08/202406:00GlobeNewswire Inc.Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
12/08/202416:02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:VIGLVigil Neuroscience Inc
01/08/202415:05GlobeNewswire Inc.Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology GeneticsNASDAQ:VIGLVigil Neuroscience Inc
30/07/202415:05GlobeNewswire Inc.Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)  NASDAQ:VIGLVigil Neuroscience Inc
24/07/202406:00GlobeNewswire Inc.Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s DiseaseNASDAQ:VIGLVigil Neuroscience Inc
18/07/202415:05GlobeNewswire Inc.Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International ConferenceNASDAQ:VIGLVigil Neuroscience Inc
18/07/202406:00GlobeNewswire Inc.Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSPNASDAQ:VIGLVigil Neuroscience Inc
27/06/202401:00GlobeNewswire Inc.Vigil Neuroscience Announces $40 Million Strategic Investment from SanofiNASDAQ:VIGLVigil Neuroscience Inc
30/05/202406:05GlobeNewswire Inc.Vigil Neuroscience to Present in Upcoming June Investor ConferencesNASDAQ:VIGLVigil Neuroscience Inc
08/05/202406:40GlobeNewswire Inc.Vigil Neuroscience to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:VIGLVigil Neuroscience Inc
07/05/202415:05GlobeNewswire Inc.Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
17/04/202415:05GlobeNewswire Inc.Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
26/03/202406:05GlobeNewswire Inc.Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
20/03/202406:05GlobeNewswire Inc.Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerNASDAQ:VIGLVigil Neuroscience Inc
13/03/202406:05GlobeNewswire Inc.Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
12/03/202406:05GlobeNewswire Inc.Vigil Neuroscience to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VIGLVigil Neuroscience Inc
06/03/202415:25GlobeNewswire Inc.Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024NASDAQ:VIGLVigil Neuroscience Inc
 Showing the most relevant articles for your search:NASDAQ:VIGL

Su Consulta Reciente

NASDAQ
NVDA
NVIDIA
COIN
DOGEUSD
Dogecoin
NYSE
BAC
Bank of America
NYSE
JPM
JP Morgan Chase
COIN
ADAUSD
Cardano
USI
USTECH100
US Tech 100
NASDAQ
QQQ
Invesco QQQ Trust Series 1
COIN
AVAXUSD
Avalanche
USOTC
ADDYY
Adidas (QX)
COIN
SOLUSD
Solana
NYSE
MCD
McDonalds
NASDAQ
TSLA
Tesla
USOTC
BASFY
BASF (QX)
NASDAQ
AAPL
Apple
NYSE
DIS
Walt Disney
AMEX
XLV
Health Care Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados